INMB - INmune Bio, Inc. Stock Price and Quote

INMB [NASD]

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	35.05%	Shs Outstand	17.95M	Perf Week	-13.17%
Market Cap	118.98M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	0.04%	Shs Float	11.66M	Perf Month	-38.31%
Income	-27.30M	PEG	-	EPS next Q	-0.02	Inst Own	10.70%	Short Float / Ratio	9.22% / 19.38	Perf Quarter	-17.44%
Sales	0.40M	P/S	297.44	EPS this Y	19.00%	Inst Trans	-4.56%	Short Interest	1.07M	Perf Half Y	-20.92%
Book/sh	3.35	P/B	1.85	EPS next Y	-26.50%	ROA	-31.40%	Target Price	18.00	Perf Year	-22.79%
Cash/sh	2.72	P/C	2.28	EPS next 5Y	-	ROE	-40.50%	52W Range	4.63 - 10.75	Perf YTD	-2.21%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-34.70%	52W High	-42.33%	Beta	2.05
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	-	Gross Margin	-	52W Low	33.94%	ATR	0.62
Employees	10	Current Ratio	5.90	Sales Q/Q	-50.00%	Oper. Margin	-	RSI (14)	28.33	Volatility	8.82% 7.63%
Optionable	Yes	Debt/Eq	0.24	EPS Q/Q	40.00%	Profit Margin	-	Rel Volume	1.66	Prev Close	6.58
Shortable	Yes	LT Debt/Eq	0.16	Earnings	Mar 02 AMC	Payout	-	Avg Volume	55.46K	Price	6.20
Recom	1.50	SMA20	-25.48%	SMA50	-26.22%	SMA200	-22.48%	Volume	92,036	Change	-5.78%

May-24-22

Downgrade

B. Riley Securities

Buy → Neutral

$14 → $7

Jul-07-21

Reiterated

Maxim Group

Buy

$32 → $42

Apr-21-21

Initiated

B. Riley Securities

Buy

$29

Jan-22-21

Reiterated

Maxim Group

Buy

$16 → $32

Sep-01-20

Initiated

BTIG Research

Buy

$23

Jul-15-20

Reiterated

H.C. Wainwright

Buy

$7 → $20

Mar-20-23 06:46AM	INmune Bio, Inc.'s (NASDAQ:INMB) top owners are retail investors with 55% stake, while 25% is held by insiders Simply Wall St. -5.78%
Mar-06-23 09:48AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-03-23 09:53AM	Q4 2022 INmune Bio Inc Earnings Call Thomson Reuters StreetEvents -7.31%
Mar-02-23 04:05PM	INmune Bio, Inc. Announces 2022 Results and Provides Business Update GlobeNewswire
Feb-21-23 09:00AM	INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 GlobeNewswire
08:45AM	Loading…
Feb-08-23 08:45AM	INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom GlobeNewswire +10.05%
Jan-25-23 07:45AM	INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy GlobeNewswire +9.33%
Dec-22-22 08:00AM	INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimers Disease GlobeNewswire
Dec-21-22 09:55AM	Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know Zacks
Dec-08-22 08:00AM	INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune GlobeNewswire +6.56%
Dec-06-22 04:00PM	INmune Bio, Inc. Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer GlobeNewswire
Nov-29-22 08:00AM	INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimers Disease Treatments GlobeNewswire
Nov-20-22 07:34AM	Quite a few insiders invested in INmune Bio, Inc. (NASDAQ:INMB) last year which is positive news for shareholders Simply Wall St.
Nov-14-22 09:00AM	INmune Bio, Inc. Receives Health Canada No Objection Letter to Commence Clinical Trial of XPro1595 in Mild Alzheimers Disease GlobeNewswire
Nov-02-22 04:00PM	INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update GlobeNewswire -6.96%
08:10AM	Loading…
Oct-26-22 08:10AM	INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2 GlobeNewswire
Oct-19-22 11:48AM	INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines Benzinga
08:00AM	INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune GlobeNewswire
Oct-10-22 11:46AM	While insiders own 25% of INmune Bio, Inc. (NASDAQ:INMB), individual investors are its largest shareholders with 54% ownership Simply Wall St.
Sep-07-22 09:00AM	INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference GlobeNewswire +6.33%
Aug-04-22 05:00AM	INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript Motley Fool
Aug-03-22 04:10PM	INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update GlobeNewswire
Jul-27-22 08:00AM	INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3 GlobeNewswire
Jul-25-22 08:00AM	INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease GlobeNewswire
Jul-17-22 08:19AM	INmune Bio (NASDAQ:INMB) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Simply Wall St.
Jun-22-22 08:00AM	USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases GlobeNewswire
Jun-16-22 08:00AM	INmune Bio, Inc. Presents Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer GlobeNewswire
Jun-09-22 07:35AM	Mizner Park office space fills up American City Business Journals +7.61%
Jun-07-22 09:55AM	Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect? Zacks
08:36AM	New Analysts Initiate Coverage: 5 Stocks for Higher Returns Zacks
06:22AM	Loading…
Jun-02-22 06:22AM	CFO, Treasurer & Secretary David Moss Just Bought A Handful Of Shares In INmune Bio, Inc. (NASDAQ:INMB) Simply Wall St.
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study Zacks +12.59%
10:06AM	Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates Zacks
May-24-22 08:59AM	INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade MarketWatch -24.62%
May-23-22 04:00PM	INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595 in Alzheimers Disease GlobeNewswire
May-18-22 09:00AM	INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th GlobeNewswire
May-10-22 08:00AM	INmune Bio, Inc. Presents Data Demonstrating XPro Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation GlobeNewswire
May-06-22 01:30PM	INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript Motley Fool
May-05-22 04:00PM	INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update GlobeNewswire -8.48%
May-03-22 11:44AM	What Type Of Shareholders Make Up INmune Bio, Inc.'s (NASDAQ:INMB) Share Registry? Simply Wall St.
Apr-28-22 07:00AM	INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5 GlobeNewswire +6.84%
Apr-25-22 04:00PM	INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference GlobeNewswire +16.20%
Apr-14-22 03:38PM	INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate Zacks
Apr-13-22 04:00PM	INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimers disease GlobeNewswire +12.12%
Apr-11-22 08:00AM	INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022 GlobeNewswire
Apr-04-22 09:00AM	INmune Bio, Inc. Highlights INKmune Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit GlobeNewswire
Mar-30-22 08:00AM	INmune Bio, Inc. Announces Companys CSO Dr. Mark Lowdell to Co-Host the NK Cells in Solid Tumors Workshop at Innate Killer Summit GlobeNewswire
Mar-25-22 09:00AM	INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD 2022 GlobeNewswire
Mar-15-22 08:00AM	INmune Bio, Inc. Announces Nine Data Presentations at AD/PD 2022 - International Conference on Alzheimer's and Parkinson's Diseases GlobeNewswire
Mar-14-22 04:30PM	INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference GlobeNewswire
Mar-04-22 04:30AM	INmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript Motley Fool
Mar-03-22 04:00PM	INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update GlobeNewswire -6.91%
Feb-23-22 09:00AM	INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3 GlobeNewswire
Feb-08-22 09:00AM	INmune Bio, Inc. to Present at the BIO CEO & Investor Conference GlobeNewswire
Feb-07-22 07:14AM	Does INmune Bio (NASDAQ:INMB) Have A Healthy Balance Sheet? Simply Wall St.
Jan-25-22 09:00AM	INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer GlobeNewswire
Jan-04-22 09:00AM	INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting GlobeNewswire -5.43%
Dec-09-21 09:01AM	INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium GlobeNewswire
Dec-01-21 09:00AM	INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial. GlobeNewswire -8.25%
Nov-15-21 08:00AM	CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors GlobeNewswire
Nov-08-21 06:34AM	How Much Of INmune Bio, Inc. (NASDAQ:INMB) Do Insiders Own? Simply Wall St. +8.55%
Nov-04-21 03:01AM	INmune Bio, Inc. (INMB) Q3 2021 Earnings Call Transcript Motley Fool -9.73%
Nov-03-21 04:15PM	INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update GlobeNewswire
Oct-27-21 09:00AM	INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimers Disease (CTAD) Annual Meeting GlobeNewswire
Oct-25-21 09:00AM	INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3 GlobeNewswire
Sep-27-21 04:00PM	INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series GlobeNewswire
Sep-23-21 12:12PM	10 Best Micro-Cap Stocks to Invest In Insider Monkey
Sep-22-21 02:44PM	Inmune Bio Stock Flashes Robust RS Rating Investor's Business Daily
Sep-20-21 04:00PM	INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences GlobeNewswire -6.27%
Sep-08-21 12:02PM	30 Stocks Moving In Wednesday's Mid-Day Session Benzinga -22.55%
Sep-02-21 04:13PM	INmune Bio Stock Rises As Small-Cap Shows Promise In Alzheimer's Disease Investor's Business Daily
11:33AM	INmune (INMB) Announces Positive Data for its AD Candidate Zacks
07:06AM	28 Stocks Moving in Thursday's Pre-Market Session Benzinga
Sep-01-21 04:45PM	Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon? Benzinga
04:00PM	Alzheimers Patients Treated with INmune Bios XPro Show Reduction in CSF Phospho-Tau and Evidence of Remyelination GlobeNewswire
Aug-26-21 12:56PM	INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial Benzinga
Aug-25-21 04:00PM	INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming Pseudokine, INKmune, Successfully Produced Memory-Like NK Cells GlobeNewswire
Aug-10-21 09:00AM	INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Aug-05-21 08:15AM	INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference GlobeNewswire +5.80%
Aug-04-21 04:20PM	INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update GlobeNewswire
Jul-28-21 04:05PM	INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4 GlobeNewswire +9.05%
Jul-26-21 08:30AM	INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimers Disease Clinical Trial and New Phase 1b AD Biomarker Data GlobeNewswire -22.98%
Jul-25-21 05:36AM	INmune Bio (NASDAQ:INMB) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jul-23-21 04:20PM	Why Annovis Stock Is Bucking The Trend In Alzheimer's And Two Others To Watch Investor's Business Daily
Jul-22-21 11:53AM	INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments PR Newswire
Jul-19-21 08:30AM	INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimers Association International Conference 2021 GlobeNewswire
Jul-14-21 11:45AM	INmune Bio Issues Equity Raise Of $40M At 18% Discount To Fund Alzheimer's Candidate Development Benzinga -13.94%
09:02AM	INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING GlobeNewswire
Jul-12-21 05:25PM	3 Healthcare Stocks That Can Become Big-Time Alzheimers Players TipRanks
08:00AM	INmune Bio, Inc. Announces First Patient Treated with NK cell priming pseudokine INKmune in High-Risk Myelodysplastic Syndrome (MDS) GlobeNewswire
Jul-07-21 09:47AM	Analyst Raises Price Targets on 3 Smaller Alzheimers Stocks Barrons.com +10.64%
Jun-14-21 04:01PM	INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution GlobeNewswire
Jun-13-21 10:59PM	Where Do Hedge Funds Stand On Inmune Bio Inc. (INMB)? Insider Monkey
Jun-02-21 09:00AM	INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN GlobeNewswire
May-24-21 09:00AM	INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021 GlobeNewswire -7.75%
May-06-21 04:01AM	INmune Bio, Inc. (INMB) Q1 2021 Earnings Call Transcript Motley Fool -5.51%
May-05-21 04:15PM	INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update GlobeNewswire
02:45PM	INmune Bio, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 09:00AM	INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5 GlobeNewswire
Apr-26-21 09:00AM	INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference GlobeNewswire

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moss David J	CFO, Treasurer & Secretary	Mar 17	Buy	6.42	2,500	16,062	1,250,151	Mar 20 08:02 AM
Moss David J	CFO, Treasurer & Secretary	May 27	Buy	6.79	3,000	20,370	1,247,651	May 31 06:08 AM
Moss David J	CFO, Treasurer & Secretary	May 26	Buy	6.27	7,700	48,279	1,244,651	May 31 06:08 AM
Tesi Raymond Joseph	President and CEO	May 26	Buy	6.41	6,300	40,383	1,520,698	May 31 06:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience